Benchmark Genetics CEO steps down just weeks after appointment to join Biomega

Benchmark Genetics has announced that Chief Executive Officer Geir Olav Melingen will step down from his role. Aleks Engel, Partner at Novo Holdings, will serve as interim CEO while the company initiates a formal search for Melingen’s successor.

Melingen has been with the Benchmark Group for six and a half years, and was appointed CEO of Benchmark Genetics on 1 April 2025, following the company’s transition to independent ownership under Novo Holdings. He previously served as Head of the Genetics business area within Benchmark Holdings.

In a post on LinkedIn, Melingen described his time at Benchmark as “an incredible journey,” noting that “the last couple of years with the strategic sales process have been educational and demanding.” He confirmed that he will join Biomega as its new CEO later this year, taking up the role no later than 1 October.

“I have great faith in what Benchmark Genetics can achieve together with Novo Holdings,” Melingen wrote. “I will contribute to a good transfer in the time to come.”

During Melingen’s tenure, Benchmark Genetics reinforced its position as a provider of genetic solutions for salmon, shrimp, and other aquaculture species.

“Geir Olav has played a central role in building Benchmark Genetics into a strong and focused organisation with a clear strategic direction,” said Aleks Engel. “On behalf of Novo Holdings and the Board, I want to thank him for his leadership and dedication.”